SUZ12 and neoplasm: Here we demonstrated that along with prostate adenocarcinoma, other tumor types show a correlation between high EZH2, SUZ12 and EED levels and a shorter survival, suggesting that these cancers could be potential targets for EZH2/SUZ12/EED inhibitor therapy.